- Home
- HRMY vs SYBT Comparison
HRMY vs SYBT Comparison
Compare HRMY & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | SYBT |
|---|---|---|
| Founded | 2017 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HRMY | SYBT |
|---|---|---|
| Price | $39.57 | $77.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 6 |
| Target Price | $47.36 | ★ $90.20 |
| AVG Volume (30 Days) | ★ 832.3K | 121.8K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.71% |
| EPS Growth | 7.97 | ★ 22.11 |
| EPS | 1.84 | ★ 2.55 |
| Revenue | ★ $868,453,000.00 | $23,406,000.00 |
| Revenue This Year | $18.74 | $15.13 |
| Revenue Next Year | $12.58 | $8.33 |
| P/E Ratio | ★ $21.33 | $30.24 |
| Revenue Growth | ★ 21.51 | 3.37 |
| 52 Week Low | $25.52 | $61.51 |
| 52 Week High | $43.49 | $89.22 |
Technical Indicators
Market Signals| Indicator | HRMY | SYBT |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 35.44 |
| Support Level | $34.87 | $74.73 |
| Resistance Level | $43.38 | $82.14 |
| Average True Range (ATR) | 1.25 | 1.73 |
| MACD | -0.42 | -0.18 |
| Stochastic Oscillator | 26.15 | 2.77 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.